ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™) [Yahoo! Finance]
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)
Promis Neurosciences (NASDAQ:PMN) was downgraded by analysts at
Wall Stre
Promis Neurosciences (NASDAQ:PMN) had its price target lowered by analysts at Guggenheim from $125.00 to $35.00. They now have a "buy" rating on the stock.
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 [Canadian Business Journal (Canada)]